




RealRate

PHARMACEUTICAL 2024

Cymabay Therapeutics Inc
Rank 90 of 309



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Cymabay Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Cymabay Therapeutics Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 109% points. The greatest weakness of Cymabay Therapeutics Inc is the variable Other Liabilities, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 292%, being 79% points above the market average of 213%.

Input Variable	Value in 1000 USD	Output Variable	Value in 1000 USD
Assets, Current	403,802	Assets	434,686
Cost of Goods Sold	0	Liabilities	142,430
Intangible Assets	0	Expenses	132,752
Liabilities, Current	36,843	Revenues	31,073
Liabilities, Non-Current	0	Stockholders Equity	292,256
Other Assets	30,419	Net Income	-105,370
Other Compr. Net Income	470	Comprehensive Net Income	-105,135
Other Expenses	0	BaseVar	372,551
Other Liabilities	105,587	ECR before LimitedLiability	184%
Other Net Income	-3,691	Economic Capital Ratio	292%
Other Revenues	31,073		
Property and Equipment	465		
Research and Development	80,799		
Selling, General and Administrative Expense	51,953		